Ridogrel: An antiplatelet agent with antihypertensive properties

Cardiovascular Drug Reviews

Volumn 18, Issue 3, 2000, Pages 222-231

  Wilson, Thomas W ^a,b   Quest, Dale W ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Department of Pharmacology ^*  (Canada)

Author keywords

Hypertension; Platelet function; Ridogrel; Thromboxane antagonists; Thromboxane synthase inhibitors

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; INDOMETACIN; RIDOGREL; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT;

ANTIHYPERTENSIVE ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERTENSION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REVIEW;

EID: 0033670105     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2000.tb00045.x     Document Type: Review

References (47)

1. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT)
2. A renal vasodilator effect of angiotensin II revealed by dual thromboxane inhibition
3. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid
4. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects
5. 2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog
6. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: Anti-inflammatory profile in inflammatory bowel disease
7. 2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets
8. Substrate for endothelial prostacyclin production in the presence of platelets exposed to collagen is derived from the platelets rather than the endothelium
9. 2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro
10. 2/prostaglandin endoperoxide receptor blockade combined in one molecule. II. Pharmacological effects in vivo and ex vivo
11. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication
12. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review
13. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy
14. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease
15. Lack of short-term effect of the thromboxane synthetase inhibitor UK-38,485 on airway reactivity to methacholine in asthmatic subjects
16. 2 receptor antagonist in human platelets
17. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders
18. Role of thromboxane in control of arterial pressure and renal function in young spontaneously hypertensive rats
19. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease
20. R 68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: A comparison with aspirin
21. 2 production
22. 2 in borderline and essential hypertension
23. 2 receptor antagonist BAY u3405 on antigen-, leukotriene C4- and leukotriene D4- induced bronchoconstriction in guinea pigs
24. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension
25. Prostacyclin stimulates the renin angiotensin aldosterone system in man
26. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension
27. Interrelationships among prostaglandins and vasoactive substances
28. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man
29. Thromboxane synthesis and blood pressure in spontaneously hypertensive rats
30. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat
31. Review article: Thromboxanes in inflammatory bowel disease - Pathogenic and therapeutic implications
32. 2 receptor antagonism and synthase inhibition in essential hypertension
33. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans?
34. 3H]-noradrenaline release and vascular tone in rat isolated kidney
35. 2 receptor antagonists and synthetase inhibitors
36. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds
37. 2 receptor antagonist
38. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction
39. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis
40. 2/prostaglandin endoperoxide receptors upon chronic administration to man
41. Modulation of renin by thromboxane: Studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic
42. Responses to furosemide in normotensive and hypertensive subjects
43. Prostaglandins, the kidney, and hypertension
44. Effects of aging on responses to furosemide
45. 2 in urine by high-performance liquid chromatography and radioimmunoassay
46. 2 synthetase inhibition and bronchodilation. VI. Indazole derivatives
47. 2 receptor